Purpose of review The goal of this article is to discuss current genomic testing options in localized prostate cancer.
INTRODUCTION
Patients diagnosed with localized prostate cancer may face multiple management decisions, including initial treatment selection and in some cases, the decision whether to undergo secondary therapy. Current methods of risk classification based on prostate specific antigen (PSA), clinical stage, and biopsy histopathology have significant limitations. Misclassification is possible with a potential impact on management decisions. To provide men with additional information on risk stratification, several genomic tests are now available. The purpose of this article is to provide a summary of the Prolaris, OncotypeDx, and genomic classifiers.
PROLARIS
Prolaris is a panel of cell cycle progression (CCP) genes measuring cancer proliferation. The primary endpoint of this test is the 10-year risk of prostate cancer death with conservative management. Using Cuzick et al. [1] examined the paraffin specimens from 349 men diagnosed with prostate cancer in 1990-1996 who were managed conservatively. After adjusting for with PSA and Gleason score, CCP score was a significant predictor of prostate cancer death [hazard ratio (HR) 1.65, 95% confidence interval (CI) 1.31-2.09].
The Prolaris test measured on biopsy has also been shown to predict outcomes after radical treatment. Freedland et al. [2] reported on 141 men diagnosed with prostate cancer from 1991 to 2006 who received external beam radiation. CCP score was a significant predictor of biochemical recurrence (HR 2.11, 1.05-4.25, P ¼ 0.034) after adjusting for PSA, Gleason score, positive cores, and use of hormonal therapy. There was also a statistically significant relationship with prostate cancer death on univariate analysis, but the number of events was small. Similarly, Bishoff et al. [3] showed that biopsy CCP scores were a significant predictor of biochemical recurrence after radical prostatectomy (HR Clinical utility studies have also been performed using surveys to ask clinicians whether the results would lead to a change in practice. For example, Shore et al. [5] surveyed 15 urologists about the influence of Prolaris results in 294 different cases, and they reported that approximately one-third of the results would potentially lead to changes in practice. Another study by Crawford et al. [6] reported changes from interventional to noninterventional management, and vice versa due to Prolaris results. Less is known about the long-term impact of changing initial management decisions on the basis of genomic test results, or how these tests fit in a context with widespread multiparametric MRI use.
Finally, Prolaris has also been studied in men who have already undergone surgery using the radical prostatectomy specimen. Cooperberg et al. [7] reported on Prolaris in 413 surgically treated patients, of which 19.9% experienced biochemical recurrence. Each unit increase in CCP score was associated with a significantly risk of biochemical recurrence (HR 1.7, 95% CI 1.3-2.4) after adjusting for the CAPRA-S postsurgical risk classification. For men who are postradical prostatectomy, the Prolaris report provides the 10-year risk of biochemical recurrence, which could be used to inform decisions regarding secondary therapy.
ONCOTYPE DX
The OncotypeDx prostate biopsy test calculates a genomic prostate score (GPS) based on genes from four different pathways involved in prostate cancer: stromal response, androgen signaling, proliferation, and cellular organization. The primary endpoint of this test is to predict the risk of adverse disease at radical prostatectomy. Unlike Prolaris and Decipher, OncotypeDx was designed for use with biopsy tissue and does not have a commercially available test for postprostatectomy risk stratification.
The initial study by Klein et al. Cullen et al. [9] subsequently validated the OncotypeDx biopsy test in independent populations of men from military hospitals. On multivariable analysis adjusting for National Comprehensive Cancer Network (NCCN) risk group, a 20-unit increase in OncotypeDX GPS associated with 3.3Â increased risk of adverse disease at RP and 2.7Â increased risk of biochemical recurrence.
Recently, these studies were combined in a patient-specific meta-analysis by Brand et al. [10 & ], which was used to update the reporting based on 732 total patients. The overall median score was 27 (range 1-74). Using NCCN risk groups alone had an AUC of 0.64 for adverse disease, which increased to 0.70 adding GPS. Instead using the CAPRA, risk classification had an AUC of 0.68 alone, which increased to 0.73 with the addition of the GPS.
Clinical utility studies indicate that OncotypeDx results may also influence decisions about patient management. Badani et al. [11] reported that the GPS was discordant to the NCCN risk category in 39% of patients, and that 18% of recommendations between active surveillance and treatment changed as a result of OncotypeDx. Clinicians also reported that the results increased their confidence in decisions. Subsequently, Whalen et al. 
KEY POINTS
Prolaris is a panel of cell cycle progression genes, which can be measured using biopsy tissue for men with untreated prostate cancer or using prostatectomy tissue for previously treated patients.
OncotypeDx is measured on biopsy tissue and predicts the risk of adverse disease at radical prostatectomy for men with low-to-intermediate-risk prostate cancer.
Decipher provides genome-wide RNA expression information and can be measured using biopsy tissue for newly diagnosed patients or radical prostatectomy tissue for men with adverse disease facing decisions about secondary therapy.
follow-up of 50 men from the clinical utility study treated by radical prostatectomy, with an AUC of 0.92 for favorable disease. To achieve more than 90% accuracy for the likelihood of favorable disease, they suggested using cutoffs of 76 and 68% for lowrisk and intermediate-risk patients, respectively.
DECIPHER
The genomic classifier is a clinical grade high-density microarray encompassing 1.4 million probes that detect coding and noncoding RNA expression levels across the genome [13] . The test can be run on small amounts of routinely collected formalin-fixed paraffin-embedded tissue, including prostate biopsy tissue and that from radical prostatectomy. Genomic signatures on this platform have been developed, locked, and validated, with most of the evidence to date describing the Genomic Classifier signature that was developed to predict metastatic progression of localized disease [13] . The expansiveness of the platform allows for the development and refinement of prognostic signatures as well as for the development of predictive signatures for treatment response, as well as for the molecular characterization of tumor subtypes [14] [15] [16] .
The Decipher Genomic Classifier consists of 22 RNA-expression-based genomic markers that are prognostic for metastatic progression and relate to cellular differentiation, cell cycle progression, cellular adhesion and motility, androgen signaling, and immune modulation. The classifier score is reported in a range from 0 to 1 and is calibrated, with each 0.1 increase in score representing a 10% increase in metastatic risk. The score is reported and in addition patients are categorized into low (0-0.44, average 0.45-0.59, and high 0.6-1 genomic risk). This score was initially developed and validated on radical prostatectomy tissue but more recently has been evaluated in prostate biopsy samples. An initial validation series included 219 high risk men who had undergone radical prostatectomy at the Mayo clinic. Here the Decipher Genomic Classifier was independently predictive of metastasis and prostate cancer-specific mortality with hazard ratios of 7.3 and 11, respectively, when moving from low to high genomic risk on multivariable analysis [17, 18] . The ability of Decipher to be prognostic for metastatic progression in the postprostatectomy setting was further validated and demonstrated similar results when performed on a natural history cohort of 260 men with NCCN intermediate or high-risk prostate cancer from the Johns Hopkins Medical Institute and in an additional cohort from the Cleveland Clinic [19, 20] . Recently, Spratt et al. [21 && ] reported a retrospective meta-analysis of the Genomic Classifier in 855 patients who had undergone radical prostatectomy, had known clinical outcomes and underwent Decipher testing. The Decipher Genomic Classifier was independently prognostic of metastasis across multiple patient subgroups (i.e., high vs. low Gleason scores, PSA levels and various clinical stages) and had a C-index for prediction of metastasis of 0.81 when considered with clinical and pathological variables.
In the postprostatectomy setting, Decipher has been evaluated for its ability to inform decisions regarding adjuvant and salvage radiation therapy [22] [23] [24] [25] . Den et al. [25] for instance compared men undergoing adjuvant or salvage radiation therapy after radical prostatectomy and found that those with high genomic risk (prostate classifier scores >0.6) had up to an 80% reduction in metastatic progression if they received adjuvant radiation therapy, whereas no significant reduction was seen in men with low genomic risk. Dalela et al. [22] more recently developed a clinical-genomic nomogram to inform patients regarding adjuvant radiation therapy. They found that patients with two or more of the risk factors of pT3b-T4 disease, Gleason 8-10 prostate cancer, lymph node invasion, or Genomic Classifier scores more than 0.6 showed an over fourfold reduction in metastasis at 10 years if adjuvant radiation was employed. These studies demonstrate that the additional information provided by the Genomic Classifier allows for more precise point estimates of risk, based on clinical, pathological, and genomic features and can help inform patients deciding on adjuvant or salvage therapy [23] . To determine clinical utility in the postoperative setting, PRO_IMPACT is a multiinstitutional prospective study to assess clinical decision-making and patient-reported outcomes after genomic classifier (NCT02080689) [26] . Use of the Decipher Genomic Classifier significantly reduced decision-conflict and patient anxiety, and resulted in changes in clinical decision-making regarding both adjuvant and salvage radiation therapy (in 18 and 32% of cases, respectively).
As mentioned above, the Decipher Genomic Classifier has also been evaluated for its independent prognostic ability in prostate biopsy tissue, using the same markers and coefficients for score calculation as are employed on prostatectomy tissue. In a study by Klein et al. [27] examining the Decipher Genomic Classifier from the biopsies of 57 men who underwent prostatectomy and had longterm follow-up, the genomic classifier was independently predictive of metastasis and increased the AUC for metastasis prediction from 0.72 for NCCN risk categories alone to 0.88 when combined with genomic testing. Nguyen et al. [28] then studied the Decipher Genomic Classifier in the biopsies of 100 patients undergoing primary radiation therapy for prostate cancer. On multivariable analysis, including clinical pathological variables individually or in nomogram scores like CAPRA, only the genomic Genomic Classifier score was independently predictive of clinical progression. This highlights the potential importance of genomic testing, particularly in intermediate-risk men considering radiation therapy.
When utilized either in the clinical or research setting, the genomic classifier acquires genomewide expression information allowing for the development and use of genomic signatures that are not just prognostic but also can molecularly subclassify tumors and predict treatment response. Locked and calibrated genomic signatures are reported with the Genomic Classifier as part of the Genomic Resource Information Database when Decipher is performed. Recently, Zhao et al. [16] developed and validated the Decipher Post-Operative Radiation Therapy Outcomes Score (PORTOS). PORTOS is a 24-gene predictor of response to postoperative radiotherapy. The score is not prognostic of metastatic outcome when no radiation therapy is utilized but is highly predictive of metastatic progression if adjuvant or salvage radiation is used, with high PORTOS scores being associated with a seven-fold reduction in metastatic progression among men receiving postoperative radiation. As PORTOS was developed with gene sets implicated in radiation response it is likely that PORTOS will predict primary response to radiation as well however evaluation of PORTOS from men undergoing primary radiation therapy has yet to be reported on. Zhao et al. [29] have also recently reported on the use of Decipher to subtype prostate cancer into luminal and basal types using PAM50 clustering as has been done with breast cancer. Paralleling findings from breast cancer, the Decipher PAM50 classifier subdivided prostate cancer into Luminal A, Luminal B, and Basal subtypes. Luminal A and B subtypes demonstrated far greater amounts of androgen signaling than basal subtypes and when compared with other subtypes, Luminal B cancers appeared to respond favorably to androgen deprivation therapy.
CONCLUSION
For men with localized prostate cancer making decisions about initial or second-line therapy, there are multiple commercially available genomic tests that can be ordered to provide additional prognostic information. The Prolaris, OncotypeDx, and genomic classifiers are available for biopsy tissue, and the Prolaris and genomic classifiers can be used after radical prostatectomy. 
